Preoperative Serum Triglyceride to High-Density Lipoprotein Cholesterol Ratio Can Predict Prognosis in Non-Small Cell Lung Cancer: A Multicenter Retrospective Cohort Study

Junhong Li¹,†, Cong Ma¹,†, Xuhui Yuan²,³, Xiaoyan Wang², Na Li¹, Ronghui Yu² and Hui Liao¹,*

¹ Department of Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
² Department of Surgery, First Affiliated Hospital of Nanchang University, Nanchang 330006, China
³ Department of Surgery, Third Affiliated Hospital of Nanchang University, Nanchang 330008, China
* Correspondence: tongji71mc@163.com
† These authors contributed equally to this work.

Abstract: Background: Previously, research has reported associations of lipid and lipoprotein imbalances with carcinogenesis and cancer progression, so they have been considered as promising prognostic biomarkers for cancer in recent years. However, the correlation of preoperative serum triglyceride to high-density lipoprotein cholesterol ratio (TG/HDL-C) with non-small cell lung carcinoma (NSCLC) prognosis remains under exploration. Here, the study investigated the prognostic function of TG/HDL-C for NSCLC. Methods: The total combined group of this retrospective study enrolled 479 NSCLC patients from two tertiary referral hospitals, of which 223 patients were defined as the training group (Nanchang) and the remaining 256 were defined as the validation group (Wuhan). The cut-off of preoperative TG/HDL-C was determined through ROC curve in the training group and verified in the validation and combined groups subsequently. With one Cox proportional hazards model and K-M survival curves, a survival analysis was conducted. Results: In the training group, the optimal cut-off of TG/HDL-C was 1.02. Furthermore, the data based on the training group revealed a greater, shorter, overall survival (OS) in patients having a high TG/HDL-C (>1.02) than those having low TG/HDL-C (≤1.02). Meanwhile, in univariate and multivariate analysis, for prognostic OS among NSCLC patients, TG/HDL-C acted as one independent factor. All the results above were confirmed in the validation and combined groups. Conclusion: NSCLC patients with a comparatively low preoperative serum TG/HDL-C level had a correlation with well OS. TG/HDL-C possibly acted as one novel, effective prognostic biomarker for NSCLC patients.

Keywords: NSCLC; triglyceride; high-density lipoprotein cholesterol; prognosis

1. Introduction

Lung cancer, the primary reason for global cancer-associated deaths, occupies over 120,000 deaths each year in the United States of America [1]. In China, lung cancer is the most frequently-seen cancer, with the highest mortality rate among all cancers [2]. Non-small cell lung cancer (NSCLC), primarily composed of lung squamous cell carcinoma, as well as adenocarcinoma, occupies about 85% of all lung cancer patients [3]. Surgical resection is the most effective therapy for stage I-II NSCLC and in a subset of cases with stage IIIA NSCLC [4]. By contrast, patients with stage IIIIB–IV NSCLC are not amenable to curative resection; therefore, thoracic radiotherapy, chemotherapy, molecular targeted therapy, and immunotherapy are alternative treatment modalities for these patients [4]. Despite the availability of various treatment options, the overall survival (OS) rates of late-stage NSCLC cases in 5 years continue to remain poor (36% 5-year OS rate in stage IIIA compared to 83% in stage IA) [5,6]. The unsatisfactory prognosis is generally attributed to the difficulty in early diagnosis and the high propensity for metastasis [7]. Moreover,
due to the heterogeneity of NSCLC, the traditional tumor-node-metastasis (TNM) staging system may not be an accurate tool for prognostic assessment of these patients, as patients at the same stage usually have different survival outcomes [8,9]. Owing to the poor long-term outcomes and the paucity of prognostic indicators, identification of more effective prognostic biomarkers for NSCLC is a key imperative to guide treatment decision-making.

Several recent studies have indicated potential roles of imbalance in serum lipid indices, such as high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), as well as cholesterol, in the causation and prognosis of cardiovascular diseases and cancer [10–12]. TG, one of the components of serum lipids with pro-cellular proliferative activity, was shown to be linked with cancer cell proliferation and differentiation, and cancer-associated cell growth [13,14]. Cholesterol, an essential structural component of lipid rafts, maintains a vital part in maintaining the structural integrity of cell membranes as well as intracellular signal transduction [15]. HDL-C can remove cholesterol from peripheral tissues and reverse-transport it to the liver, and thus can be regarded as a potent antioxidant and anti-inflammatory factor [16]. The metabolism of serum lipids and lipoproteins, such as TG and HDL-C, has a strong correlation to the nutritional status of patients (BMI), diet, and stressful metabolic states [17]. Reportedly, abnormalities in serum lipids and lipoproteins are strongly bound up with the development as well as the progression of cancer, suggesting that their potential roles in carcinogenesis and providing an innovative theoretical basis for anticancer treatment [18–21]. Until now, some studies have identified reduced serum HDL-C levels as one risk factor for ovarian cancer, hepatocellular, and nasopharyngeal carcinoma [17,22,23]. Conversely, Wang et al. [24] found upregulated serum HDL-C as one risk factor for colorectal cancer. Thus, there is no clear consensus on the pathological relationship between dyslipidemia and cancer. Additionally, the correlation of TG and HDL-C levels with cancer prognosis is not well characterized, especially in the context of NSCLC. In only limited studies, serum TG or HDL-C was linked to the prognosis of NSCLC patients [25–27].

Interestingly, Sun et al. [28] found a higher sensitivity and predictive function of TG/HDL-C in the prognostic assessment for gastric cancer when compared with any single lipid parameter. They observed that, when compared with those of other serum lipids (TC, LDL-C, HDL-C, as well as TG), TG/HDL-C showed the largest AUC in independent forecasting of 5-year OS among gastric cancer patients [28]. Retrospective cohort research by Dai D. et al. also indicated TG/HDL-C as one independent predictive biomarker for OS among triple-negative breast cancer patients, with an advantage over the serum TG level [29]. Indeed, each single lipid parameter reflected only one aspect of interaction with cancer. Use of an index that combines multiple parameters may unravel the association between cancer and lipid metabolism with a higher accuracy and sensitivity [18,28,29]. According to previous research by Ma et al. [25], preoperative serum TG and HDL-C can be factors for independent outcome prediction among NSCLC patients. However, the link of TG/HDL-C with NSCLC prognosis remains unknown, which is also the original intention of our current research.

Therefore, with a multicenter retrospective cohort design, this study was for investigating the prognostic function of preoperative TG/HDL-C among NSCLC patients.

2. Methods

2.1. Study Population

The Ethics Committee of Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, as well as First Affiliated Hospital of Nanchang University approved this retrospective research (reference number: TJ-IRB20220802). A total of 479 NSCLC patients from these two tertiary referral hospitals were enrolled and further defined as the training group (Nanchang, $n = 223$) or the validation group (Wuhan, $n = 256$), respectively. The inclusion criteria: cases ≥18 years who were pathologically diagnosed as NSCLC (stages I-IIIA); availability of complete clinical data; blood samples were collected before therapy. The exclusion criteria: (1) patients who had received neoadju-
vant chemoradiotherapy; (2) those with malignancies that originated from any organ other than the lung; (3) those receiving any drug that affected lipid metabolism; (4) presence of concomitant diseases associated with deranged lipid metabolism, such as hyperlipidemia, diabetes, or metabolic syndrome; (5) history of blood transfusion in the four-month period immediately preceding the hospital admission.

Patients in the training group were diagnosed and treated in the First Affiliated Hospital of Nanchang University between March 2013 and September 2018. Patients in the validation group were diagnosed and treated at the Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology from October 2014 to October 2019. The diagnosis and stage of NSCLC were determined in accordance with the criteria of the Union for International Cancer Control (2017 UICC-8 criteria). According to the perioperative management principles, every patient was asked to stop smoking and alcohol consumption within 14 days before operation, and were given a light diet. The therapy protocols of 479 patients were developed and implemented under the instructions from the National Comprehensive Cancer Network.

2.2. Follow-up

Every patient was followed up under the recommendations of the 2017 UICC-8. Follow-up was made to patients who were discharged after therapy every 3 months for the first 2 years, and every 6 months for the next 3–5 years, and then annually thereafter. In the training group, follow-up ended on patient death or 30 November 2020, and in the validation group, the follow-up terminated on 30 November 2021, or death.

2.3. Statistical Processing

Statistical processing was performed via IBM SPSS 23.0 (SPSS, Chicago, IL, USA) as well as GraphPad Prism 7.00 (GraphPad Software, La Jolla, CA, USA). The Kolmogorov-Smirnov test was adopted for assessing the distribution normality of continuous variables. Those in normal distribution were reported by mean ± SD, and others were presented as median (first-third interquartile range [IQR]). Categorical variables (frequency (%)) were assessed using the chi-squared test. Receiver operative characteristics (ROC) curve analysis was performed for determining optimal cut-off and the area under the ROC curve (AUC) of preoperative TG/HDL-C in OS prediction. Survival analysis was conducted using K-M curves and the independent prognostic factors were determined though a Cox proportional hazards model. Two-sided $p$ values < 0.05 suggested a notable difference.

3. Results

3.1. Patients’ Characteristics in Two Independent NSCLC Cohorts

Table 1 depicts patients’ detailed baseline characteristics. A total number of 479 patients with NSCLC which met our inclusion criteria were identified and enrolled here, including 223 and 256 in the training group and validation group, respectively. For the total combined group, 150 (31.3%) were women and 329 (68.9%) were men. The number of NSCLC patients accepted adjuvant chemotherapy in the training and validation groups, respectively, were 116 (52.0%) and 161 (62.9%). In the training group, 125 out of 223 patients survived at the last follow-up, 104 deaths were found during the whole follow-up in the validation group. Therefore, the OS ratios were 56.1% and 59.4% for training and validation groups, respectively. The baseline clinicopathological parameters in both cohorts were comparable.

3.2. Identifications of Optimal Cut-Off Value of TG/HDL-C Derived from the Training Group

We identified the optimal cut-off of TG/HDL-C and the corresponding AUC in NSCLC via ROC curve-based analysis. Using OS as the primary treatment outcome in the training group, the optimal cut-off of TG/HDL-C having the highest sensitivity and specificity was 1.02 ($p = 0.005$, AUC: 0.632, 95% CI 0.559–0.706). In the light of the optimal cut-off, the
patients were assigned to high TG/HDL-C (TG/HDL-C > 1.02) and low TG/HDL-C group (that ≤1.02).

Table 1. The clinical characteristics of subjects in the training, validation, and combined cohorts.

| Characteristics                              | Training Cohort | Validation Cohort | Combined Cohort |
|---------------------------------------------|-----------------|-------------------|-----------------|
|                                             | N = 223 %       | N = 256 %         | N = 479 %       |
| Age (years)                                 | 60.80 ± 10.75   | 59.91 ± 10.94     | 60.32 ± 10.85   |
| Gender                                       |                 |                   |                 |
| Male                                         | 156             | 173               | 329             |
| Female                                       | 67              | 83                | 150             |
| Smoking history                              |                 |                   |                 |
| Yes                                          | 152             | 159               | 311             |
| No                                           | 71              | 97                | 168             |
| Stage                                        |                 |                   |                 |
| I-II                                         | 153             | 155               | 308             |
| IIIA                                         | 70              | 101               | 171             |
| Pathological tumor classification (pT)       |                 |                   |                 |
| pT1-2                                        | 196             | 216               | 412             |
| pT3-4                                        | 27              | 40                | 67              |
| Pathological lymph node stage (pN)          |                 |                   |                 |
| pN0                                          | 134             | 128               | 262             |
| pN1-2                                        | 89              | 128               | 217             |
| Histological type                            |                 |                   |                 |
| Squamous cell carcinoma                      | 71              | 76                | 147             |
| Adenocarcinoma                               | 137             | 154               | 291             |
| Large cell carcinoma                         | 15              | 26                | 41              |
| Surgery type                                 |                 |                   |                 |
| Lobectomy                                    | 170             | 174               | 344             |
| Pneumonectomy                                | 41              | 62                | 103             |
| Other                                        | 12              | 20                | 32              |
| Adjuvant chemotherapy                        |                 |                   |                 |
| Yes                                          | 116             | 161               | 277             |
| No                                           | 107             | 95                | 202             |
| TG/HDL-C                                     | 1.16 ± 0.93     | 1.27 ± 0.87       | 1.22 ± 0.90     |

Continuous variables with normality were presented as mean ± standard deviation. Categorical variables were shown as percentages.

3.3. Relation of the TG/HDL-C with Multiple Clinicopathologic Values

The relations of the TG/HDL-C with various clinicopathologic parameters were shown in Table 2. High or low group of TG/HDL-C levels were greatly different with pN in the training group (p = 0.002), validation group (p = 0.006), as well as combined group (p < 0.001). Moreover, different TG/HDL-C groups had strong relations with histological type in the training cohort (p = 0.038).

3.4. Prognostic Value of Preoperative TG/HDL-C in the Training Cohort

For further determination of the significance of TG/HDL-C for prognostic NSCLC, we next plotted K–M curves and performed univariate and multivariate Cox proportional hazards models using data from the training group. Patients having high TG/HDL-C presented much shorter OS than those having low TG/HDL-C in the training group (Figure 1A). Univariate Cox proportional hazards model revealed a significant association of stage, pT, pN, adjuvant chemotherapy, surgery type, as well as TG/HDL-C with OS in the training group (all p < 0.05, Table 3). Multivariate Cox proportional hazards model identified TG/HDL-C as one factor for independent OS prediction in the training group (HR: 1.674, 95% CI 1.094–2.559, p = 0.017).
Table 2. Correlations between TG/HDL-C and multiple clinical parameters in NSCLC patients.

| Characteristics                  | Training Cohort (N = 223) | Validation Cohort (N = 256) | Combined Cohort (N = 479) |
|----------------------------------|---------------------------|-----------------------------|----------------------------|
|                                  | Low | High | p Value | Low | High | p Value | Low | High | p Value |
| Age (years)                      |     |      |         |     |      |         |     |      |         |
| ≤60                              | 49  | 50   | 0.500   | 72  | 53   | 0.059   | 121 | 103  | 0.357   |
| >60                              | 67  | 57   | 0.404   | 60  | 71   | 0.455   | 127 | 128  | 0.264   |
| Gender                           |     |      |         |     |      |         |     |      |         |
| Male                             | 84  | 72   |         | 92  | 81   |         | 176 | 153  |         |
| Female                           | 32  | 35   |         | 40  | 43   |         | 72  | 78   |         |
| Smoking history                  |     |      |         |     |      |         |     |      |         |
| Yes                              | 79  | 73   | 0.985   | 85  | 74   | 0.437   | 164 | 147  | 0.568   |
| No                               | 37  | 34   | 0.985   | 47  | 50   | 0.437   | 84  | 84   | 0.568   |
| Stage                            |     |      |         |     |      |         |     |      |         |
| I-II                            | 86  | 67   | 0.064   | 83  | 72   | 0.431   | 169 | 139  | 0.069   |
| IIIA                            | 30  | 40   | 0.064   | 49  | 52   | 0.431   | 79  | 92   | 0.069   |
| Pathological tumor classification(pT) |     |      |         |     |      |         |     |      |         |
| pT1-2                           | 102 | 94   | 0.002   | 110 | 106  | 0.002   | 212 | 200  | 0.002   |
| pT3-4                           | 14  | 13   | 0.002   | 22  | 18   | 0.002   | 36  | 31   | 0.002   |
| Pathological lymph node stage(pN) |     |      |         |     |      |         |     |      |         |
| pN0                             | 81  | 53   | 0.002   | 77  | 51   | 0.002   | 158 | 104  | 0.002   |
| pN1-2                           | 35  | 54   | 0.002   | 55  | 73   | 0.002   | 90  | 127  | 0.002   |
| Histological type               |     |      |         |     |      |         |     |      |         |
| Squamous cell carcinoma         | 45  | 26   | 0.038   | 36  | 40   | 0.038   | 81  | 66   | 0.038   |
| Adenocarcinoma                  | 62  | 75   | 0.038   | 81  | 73   | 0.038   | 143 | 148  | 0.038   |
| Large cell carcinoma            | 9   | 6    | 0.038   | 15  | 11   | 0.038   | 24  | 17   | 0.038   |
| Surgery type                    |     |      |         |     |      |         |     |      |         |
| Lobectomy                       | 92  | 78   | 0.496   | 94  | 80   | 0.496   | 186 | 158  | 0.496   |
| Pneumonectomy                   | 18  | 23   | 0.496   | 27  | 35   | 0.496   | 45  | 58   | 0.496   |
| Other                           | 6   | 6    | 0.496   | 11  | 9    | 0.496   | 17  | 15   | 0.496   |
| Adjuvant chemotherapy           |     |      |         |     |      |         |     |      |         |
| Yes                             | 55  | 61   | 0.152   | 78  | 83   | 0.152   | 133 | 144  | 0.152   |
| No                              | 61  | 46   | 0.152   | 54  | 41   | 0.152   | 115 | 87   | 0.152   |

Data were present with chi-square test; p < 0.05 was considered significant.

Figure 1. The Kaplan–Meier curves analysis for OS in NSCLC patients stratified by TG/HDL-C from the training (A), validation (B), and combined cohorts (C).
Table 3. Univariate and multivariate Cox proportional hazards model analyses for overall survival in the training and validation cohorts.

| Characteristics | Training Cohort | Validation Cohort |
|-----------------|----------------|------------------|
|                 | Univariate Analysis | Multivariate Analysis | Univariate Analysis | Multivariate Analysis |
|                 | HR 95%CI | p Value | HR 95%CI | p Value | HR 95%CI | p Value | HR 95%CI | p Value |
| Age (years)     |          |        |          |        |          |        |          |        |
| ≤60             | 1.000    | Reference | 1.000    | Reference | 0.127   | 0.412  |          |        |
| >60             | 1.370    | 0.914–2.054 | 1.176    | 0.798–1.732 |          |        |
| Gender          |          |        |          |        |          |        |          |        |
| Male            | 1.000    | Reference | 1.000    | Reference | 0.281   | 0.802  |          |        |
| Female          | 0.781    | 0.499–1.224 | 0.949    | 0.628–1.434 |          |        |
| Smoking history |          |        |          |        |          |        |          |        |
| Yes             | 1.000    | Reference | 1.000    | Reference | 0.783   | 0.417  |          |        |
| No              | 0.942    | 0.615–1.442 | 0.846    | 0.564–1.268 |          |        |
| Stage           |          |        |          |        |          |        |          |        |
| I–II            | 1.000    | Reference | 1.000    | Reference | <0.001  | 0.003  | <0.001   | 0.029  |
| IIIA            | 4.289    | 2.854–6.444 | 2.734    | 1.401–5.334 | 3.553   | 2.380–5.203 | 2.196   | 1.086–4.439 |
| Pathological tumor classification (pT) |          |        |          |        |          |        |          |        |
| pT1-2           | 1.000    | Reference | 1.000    | Reference | 0.002   | 0.840  |          |        |
| pT3-4           | 2.269    | 1.357–3.795 | 1.071    | 0.552–2.076 | 1.477   | 0.906–2.409 |          |        |
| Pathological lymph node stage (pN) |          |        |          |        |          |        |          |        |
| pN0             | 1.000    | Reference | 1.000    | Reference | <0.001  | 0.001  | <0.001   | <0.001 |
| pN1-2           | 3.531    | 2.341–5.326 | 3.360    | 1.608–7.021 | 4.519   | 2.876–7.096 | 4.894   | 2.386–8.039 |
| Histological type |          |        |          |        |          |        |          |        |
| Squamous cell carcinoma | 1.000    | Reference | 1.000    | Reference | 0.184   | 0.367  |          |        |
| Adenocarcinoma  | 1.008    | 0.647–1.571 | 0.899    | 0.581–1.391 |          |        |
| Large cell carcinoma | 1.920    | 0.906–4.068 | 1.404    | 0.718–2.743 |          |        |
| Surgery type    |          |        |          |        |          |        |          |        |
| Lobectomy       | 1.000    | Reference | 1.000    | Reference | <0.001  | 0.086  | <0.001   | 0.109  |
| Pneumonectomy   | 3.364    | 2.146–5.274 | 1.967    | 1.048–3.693 | 2.605   | 1.728–3.927 | 1.379   | 0.797–2.386 |
| Other           | 3.329    | 1.643–6.743 | 1.288    | 0.508–3.264 | 1.525   | 0.727–3.199 | 0.633   | 0.275–1.455 |
| Adjuvant chemotherapy |          |        |          |        |          |        |          |        |
| Yes             | 1.000    | Reference | 1.000    | Reference | 0.042   | <0.001 | 0.001    | 0.008  |
| No              | 1.519    | 1.014–2.275 | 3.616    | 1.872–6.987 | 2.155   | 1.386–3.350 | 2.803   | 1.306–6.017 |
| TG/HDL-C        |          |        |          |        |          |        |          |        |
| Low             | 1.000    | Reference | 1.000    | Reference | 0.001   | 0.017  | <0.001   | 0.007  |
| High            | 1.974    | 1.317–2.961 | 1.674    | 1.094–2.559 | 2.236   | 1.490–3.336 | 1.770   | 1.173–2.672 |

Data were analyzed by Cox proportional hazards model; p < 0.05 was considered significant.

3.5. Verification of the TG/HDL-C in the Validation Group and Combined Group

K–M analysis revealed a relation of low TG/HDL-C with longer OS in the validation group (Figure 1B). In Table 3, the univariate model revealed a significant association of TG/HDL-C with OS in the validation group (HR: 2.236, 95% CI 1.499–3.336, p < 0.001). Moreover, the multivariate model further identified TG/HDL-C as one factor for independent OS prediction in the validation group (HR: 1.770, 95% CI 1.173–2.672, p = 0.007).

We combined the training and validation groups into a joined group for further survival analysis (Table 4). As indicated in Figure 1C, patients having high TG/HDL-C had a poor OS than those having low TG/HDL-C. According to univariate analyses, pT, stage, pN, surgery type, adjuvant chemotherapy, and TG/HDL-C were bound up with OS (all p < 0.05). According to multivariate analyses, pN (p < 0.001), stage (p < 0.001), adjuvant chemotherapy (p < 0.001), surgery type (p = 0.046), and TG/HDL-C (p < 0.001) were factors for independent OS prediction of NSCLC patients. Thus, the results of validation and combined groups were similar to those obtained from the training group.
Table 4. Univariate and multivariate Cox proportional hazards model analyses for overall survival in the combined cohorts.

| Characteristics                  | Combined Cohort |          |          |          |          |          |          |          |          |
|----------------------------------|----------------|----------|----------|----------|----------|----------|----------|----------|----------|
|                                  |                | Univariate Analysis | Multivariate Analysis | Univariate Analysis | Multivariate Analysis | Univariate Analysis | Multivariate Analysis |
|                                  |                | HR  | 95%CI   | p Value  | HR  | 95%CI   | p Value  |
| Age (years)                      |                | 0.097|         |          | 0.097|         |          |
| ≤60                              |                | 1.000| Reference |          | 1.000| Reference |          |
| >60                              |                | 1.267| 0.958–1.675 | 0.337 | 1.267| 0.958–1.675 | 0.337 |
| Gender                           |                | 0.337|         |          | 0.337|         |          |
| Male                             |                | 1.000| Reference |          | 1.000| Reference |          |
| Female                           |                | 0.862| 0.636–1.167 |          | 0.862| 0.636–1.167 |          |
| Smoking history                  |                | 0.416|         |          | 0.416|         |          |
| Yes                              |                | 1.000| Reference |          | 1.000| Reference |          |
| No                               |                | 0.885| 0.660–1.187 |          | 0.885| 0.660–1.187 |          |
| Stage                            |                | <0.001|         |          | <0.001|         |          |
| I-II                             |                | 1.000| Reference |          | 1.000| Reference |          |
| IIIA                             |                | 3.789| 2.851–5.35 |          | 3.789| 2.851–5.35 |          |
| Pathological tumor classification |                | 0.002|         |          | 0.619|         |          |
| pT1-2                            |                | 1.000| Reference |          | 1.000| Reference |          |
| pT3-4                            |                | 1.756| 1.233–2.502 | 1.117 | 1.756| 1.233–2.502 | 1.117 |
| Pathological lymph node stage(pN)|                | <0.001|         |          | <0.001|         |          |
| pN0                              |                | 1.000| Reference |          | 1.000| Reference |          |
| pN1-2                            |                | 3.877| 2.872–5.23 |          | 3.877| 2.872–5.23 |          |
| Histological type                |                | 0.097|         |          | 0.097|         |          |
| Squamous cell carcinoma          |                | 1.000| Reference |          | 1.000| Reference |          |
| Adenocarcinoma                   |                | 0.946| 0.693–1.292 |          | 0.946| 0.693–1.292 |          |
| Large cell carcinoma             |                | 1.578| 0.958–2.598 |          | 1.578| 0.958–2.598 |          |
| Surgery type                     |                | <0.001|         |          | 0.046|         |          |
| Lobectomy                        |                | 1.000| Reference |          | 1.000| Reference |          |
| Pneumonectomy                    |                | 2.848| 2.106–3.851 | 1.545 | 2.848| 2.106–3.851 | 1.545 |
| Other                            |                | 2.107| 1.266–3.509 | 0.864 | 2.107| 1.266–3.509 | 0.864 |
| Adjuvant chemotherapy            |                | <0.001|         |          | <0.001|         |          |
| Yes                              |                | 1.000| Reference |          | 1.000| Reference |          |
| No                               |                | 1.767| 1.317–2.370 | 3.486 | 1.767| 1.317–2.370 | 3.486 |
| TG/HDL-C                         |                | <0.001|         |          | <0.001|         |          |
| Low                              |                | 1.000| Reference |          | 1.000| Reference |          |
| High                             |                | 2.108| 1.586–2.801 | 1.715 | 2.108| 1.586–2.801 | 1.715 |

Data were analyzed by Cox proportional hazards model; p < 0.05 was considered significant.

3.6. Predictive Performance of TG/HDL-C for NSCLC

We further investigated the prognostic function of TG/HDL-C using the AUC calculated by ROC curve. According to Figure 2, the AUC for TG/HDL-C was 0.632 (95% CI 0.559–0.706, p = 0.005), 0.656 (95% CI 0.589–0.724, p = 0.001), as well as 0.644 (95% CI 0.594–0.693, p = 0.001) in the training, validation, as well as combined groups, respectively. Collectively, these findings revealed that, with respect to predicting OS for patients with NSCLC for prognosis, TG/HDL-C has a good performance.
However, the cut-off value in this multicenter retrospective study (1.02) was different from that in triple negative breast cancer (0.600) and gastric cancer (1.20), which may be attributed to differences in cancer type, cancer stage, and number of patients. A retrospective study of Ma et al. [25] proved the association of the preoperative upregulated TG and downregulated HDL-C with an unfavorable prognosis in patients who died from NSCLC. Furthermore, Luo et al. [26] reported that relatively high HDL-C before adjuvant chemotherapy were independent prognostic factors with longer disease-free survival for NSCLC patients. Meanwhile, Lv et al. [30] revealed that the decrease in HDL-C level could indicate liver dysfunction caused by adjuvant chemotherapy in NSCLC, which partly supported the predictive significance of TG/HDL-C for patient prognosis. Additionally, prior research had also shown that lipid imbalances, including elevated TG levels or decreased HDL-C levels, enabled to predict a poorer prognosis in ovarian, colorectal, and breast cancer [17,31,32].

De novo lipogenesis and exogenous lipid uptake were the two important sources of lipids for cancer cells, and lipid levels in cancer were determined by both of these factors [33]. McLaughlin et al. [34] discovered the ability of TG/HDL-C to serve as one alternative biomarker of insulin resistance, which further stimulated TG production through lipolysis and de novo lipogenesis in the liver.

Our findings showed the ability of preoperative TG/HDL-C to act as one independent biomarker in OS prediction of patients with NSCLC. The prognostic function of TG/HDL-C in NSCLC cases was possibly attributable to the following reasons. For nearly two decades, a mountain of evidence has implicated both oxidative stress and chronic inflammation as pivotal factors regarding the causation of carcinogenesis and cancer progression [35–37]. Sustained oxidative stress induced chronic inflammation by activating the inflammation-associated transcription factors such as NF-κB, p53, PPAR-γ, AP-1, and Nrf2 [35]. The subsequent chronic inflammation induced transformation of normal cells into cancer cells through the activation of inflammatory signaling pathways [36]. An increasing body of evidence suggested a pro-carcinogenic effect of upregulated TG and downregulated HDL-C, due to their close involvement in oxidative stress and chronic inflammation [25].
Reactive oxygen species (ROS)-induced oxidative stress can upregulate TG levels, and high TG levels further induce carcinogenesis, for example, by activating the MAPK and PI3K/AKT signaling pathways [38]. Furthermore, TG-rich remnant also stimulated the growth and proliferation of cancer cells through G protein-coupled receptor [39]. Of note, in the study by Koohestani et al. [40], high serum TG level was found to promote colon tumorigenesis in high-fat diet rats as compared to those having normal TG levels. In contrast, Wang et al. [41] found that nude mice having low serum TG levels induced by low-fat diet presented strong inhibition of the growth of human prostate LNCaP tumor cells. Furthermore, clinical research had demonstrated the correlation of high TG level with increased morbidity and poor prognosis in NSCLC patients, also suggesting the pro-cancer potential of TG [25,42].

Cholesterol metabolites had also been implicated in the development of various cancers [15]. Mitochondrial cytochrome P450 family enzymes metabolize cholesterol to synthesize steroids, such as estrogen [15,43]. Estrogen can stimulate cancer cell proliferation in NSCLC patients through genomic and non-genomic signaling pathways [44]. Moreover, Wang et al. [45] found that the accumulation of intracellular cholesterol in KRAS<sup>G12C</sup> inhibitor-treated NSCLC cells may result in adaptive resistance of tumors against targeted MAPK pathway inhibitors. Conversely, HDL-C removed cholesterol from peripheral tissues by reverse transporting cholesterol to the liver, and thus could be regarded as a potent anti-cancer factor [16]. HDL-C could exhibit anti-inflammatory, anti-proliferative, and anti-oxidant properties, thereby exerting anticancer potential in the tumor microenvironment [46,47]. HDL-C acted as an antioxidant by hydrolyzing oxidized lipids and preventing lipid peroxidation in biological membranes via the enzyme paraoxonase-1 [48]. Additionally, HDL-C was able to suppress the elevation of pro-inflammatory factors and adhesion molecules such as tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β), IL-6, as well as intercellular adhesion molecule-1, thereby enhancing its anti-inflammatory effect [47]. Furthermore, multiple overlapping mechanisms were found to mediate the anti-inflammatory effect of HDL-C in several cell types [49]. Therefore, reduced HDL-C level in the setting of oxidative stress and chronic inflammation also impaired its above-mentioned functions, thereby establishing a pro-cancer microenvironment. Overall, higher TG level and lower HDL-C level may potentially indicate the progression of inflammation and oxidative stress in the tumor microenvironment, and thus help predict poorer clinical outcomes in cancer patients [17,22].

5. Strengths and Limitations

It is noteworthy that the present study first unveiled the ability of preoperative serum TG/HDL-C level to serve as an independent prognosis factor in NSCLC. Clinically, TG/HDL-C was probably considered as a valuable predictive biomarker that could determine NSCLC patients with shorter OS, thus enhancing the quality of life for the special patient groups through modifying individualized clinical therapy and strengthening the surveillance.

The strength of the present study was that the hematological parameters involved in the TG/HDL-C used to predict NSCLC prognosis were easily obtained from preoperative routine serum tests. Compared with traditional TNM staging system, serum lipids and lipoproteins had the characteristics of routine preoperative collection, cheap and non-invasion, which made TG/HDL-C more suitable for early preoperative evaluation of prognosis in developing countries. Additionally, TG/HDL-C combining information from two negatively correlated variables may have been more meaningful as a biomarker, with superior attributes of simplicity compared with any single lipid indicator [25]. TG/HDL-C reflected the TG and HDL-C levels and contained the interrelationship between the two factors, thus the ratio had a higher sensitivity and predictive significance for assessing the prognosis in cancer when compared with any single lipid parameter, such as TG, TC, HDL-C, as well as LDL-C [28]. Moreover, our study was designed as one multi-center study, and the patients enrolled in the training and validation group were from two tertiary...
referral hospitals in Wuhan and Nanchang, respectively. Compared with the more common single-center retrospective studies in the past, the current study tried to avoid the potential bias. Further, the present multi-center study included a larger sample size than other similar studies.

This research still had some shortcomings. First, in the retrospective research with a comparatively limited sample size, the impact from selection bias cannot have been ruled out. Secondly, although we demonstrated the prognostic value of TG/HDL-C, we did not compare its predictive ability with that of other known prognostic markers. Third, owing to the small number of cases of large cell lung cancer included in this study, our findings may not have been entirely representative of the clinical status of patients with this histologic type. Lastly, due to differences in patient numbers and cancer stage, the cut-off value of TG/HDL-C varied in prior research. Large-scale prospective studies are needed for determining the unified TG/HDL-C cut-off value and verifying our results. Furthermore, basic experiments are needed for unraveling the pathological mechanism among TG, HDL-C, and NSCLC.

6. Conclusions

In conclusion, our findings first evaluated and demonstrated the prognostic function of preoperative serum TG/HDL-C levels for NSCLC. Low TG/HDL-C level likely acts as a novel and effective prognostic biomarker of favorable OS in NSCLC patients. Clinically, determining lipid biomarkers associated with NSCLC prognosis can be of great importance to predict the survival, guide individualized clinical therapy, and to improve outcomes.

Author Contributions: H.L. designed the current study and amended the paper. J.L. and C.M. were the primary writers of the paper, tested the entire index for all samples, and were responsible for the statistical analysis. J.L. made critical revisions to the manuscript and created all tables and figures. J.L., C.M., X.Y., X.W., N.L. and R.Y. performed the literature search, data collection, and follow-up. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The ethics committee belonging to Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology and First Affiliated Hospital of Nanchang University ratified the current study (reference number: TJ-IRB20220802), which was implemented with the Declaration of Helsinki.

Informed Consent Statement: Patient consent was waived due to this observational study only using the information recorded on electronic medical record and the waiver of informed consent will not adversely affect the rights or welfare of the subjects.

Data Availability Statement: The data that supports the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Conflicts of Interest: The authors declared no conflict of interests.

Abbreviations

NSCLC: non-small cell lung cancer; TG: triglyceride; HDL-C: high-density lipoproteins cholesterol; TG/HDL-C: triglyceride to high-density lipoprotein cholesterol ratio; OS: overall survival; TNM: tumor-node-metastasis; UICC: Union for International Cancer Control; pT: pathological tumor classification; pN: pathological lymph node stage; ROC: receiver operating characteristic curve; AUC: area under the receiver operating characteristic curve; HR: hazard ratio; CI: confidence interval; TNF-α: tumor necrosis factor α; IL: interleukin.
25. Ma, C.; Wang, X.; Guo, J.; Liu, P. Prognostic value of preoperative serum triglycerides and high-density lipoproteins cholesterol in patients with non-small cell lung cancer: A retrospective study. Lipids Health Dis. 2021, 20, 69. [CrossRef]

26. Luo, F.; Zeng, K.M.; Cao, J.X.; Zhou, T.; Lin, S.X.; Ma, W.J.; Yang, Y.P.; Zhang, Z.H.; Lu, F.T.; Huang, Y.; et al. Predictive value of a reduction in the level of high-density lipoprotein-cholesterol in patients with non-small-cell lung cancer undergoing radical resection and adjuvant chemotherapy: A retrospective observational study. Lipids Health Dis. 2021, 20, 109. [CrossRef]

27. Chi, F.D.; Liu, W.; Chen, H.; Zhang, J.P.; Lin, Y.; Zheng, X.; Liu, W.; Dai, S. High-density lipoprotein cholesterol is a favorable prognostic factor and negatively correlated with C-reactive protein level in non-small cell lung carcinoma. PLoS ONE 2014, 9, e91080. [CrossRef]

28. Sun, H.; Huang, X.; Wang, Z.; Zhang, G.; Mei, Y.; Wang, Y.; Nie, Z.; Wang, S. Triglyceride-to-high density lipoprotein cholesterol ratio predicts clinical outcomes in patients with gastric cancer. J. Cancer 2019, 10, 6829–6836. [CrossRef]

29. Dai, D.; Chen, B.; Wang, B.; Tang, H.; Li, X.; Zhao, Z.; Li, X.; Xie, X.; Wei, W. Pretreatment TG/HDL-C Ratio Is Superior to Triacylglycerol Level as an Independent Prognostic Factor for the Survival of Triple Negative Breast Cancer Patients. J. Cancer 2016, 7, 1747–1754. [CrossRef]

30. Lv, Y.; Ding, X.S.; Li, Y.; An, X.; Miao, L.Y. High BMI and low HDL-C predict the chemotherapy-related hepatic dysfunction in Chinese advanced NSCLC patients. Cancer Biomark. Sect. A Dis. Markers 2016, 16, 89–97. [CrossRef]

31. Lofterod, T.; Mortensen, E.S.; Nawoga, H.; Wilsgaard, T.; Frydenberg, H.; Risberg, T.; Eggen, A.E.; McTernan, A.; Aziz, S.; Wist, E.A.; et al. Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes. BMC Cancer 2018, 18, 654. [CrossRef] [PubMed]

32. Chen, X.Q.; Fu, P.W.; Liu, D.H.; Yan, S.J.; Shen, X.M.; Yang, L.Y. Prognostic significance of high triglyceride and apolipoprotein B levels in patients with stage III and high-risk stage II colorectal cancer undergoing curative surgery. Oncol. Lett. 2020, 20, 705–714. [CrossRef] [PubMed]

33. Wallace, M.; Metallo, C.M. Tracing insights into de novo lipogenesis in liver and adipose tissues. Semin. Cell Dev. Biol. 2020, 108, 65–71. [CrossRef] [PubMed]

34. McLaughlin, T.; Reaven, G.; Abbasi, F.; Lamendola, C.; Saad, M.; Waters, D.; Simon, J.; Krauss, R.M. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am. J. Cardiol. 2005, 96, 399–404. [CrossRef]

35. Reuter, S.; Gupta, S.C.; Chaturvedi, M.M.; Aggarwal, B.B. Oxidative stress, inflammation, and cancer: How are they linked? Free Radic. Biol. Med. 2010, 49, 1603–1616. [CrossRef]

36. Zhao, H.; Wu, L.; Yan, G.; Chen, Y.; Zhou, M.; Wu, Y.; Li, Y. Inflammation and tumor progression: Signaling pathways and targeted intervention. Signal. Transduct. Target. Ther. 2021, 6, 263. [CrossRef]

37. Hayes, J.D.; Dinkova-Kostova, A.T.; Tew, K.D. Oxidative Stress in Cancer. Cancer Cell 2020, 38, 167–197. [CrossRef]

38. Arthur, R.; Moller, H.; Harno, H.; Holmberg, L.; Stattin, P.; Malmsstrom, H.; Lambe, M.; Hammar, N.; Walldius, G.; Robinson, D.; et al. Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories. Cancer Med. 2016, 5, 1307–1318. [CrossRef]

39. Sekine, Y.; Koike, H.; Nakano, T.; Nakajima, K.; Suzuki, K. Remnant lipoproteins stimulate proliferation and activate MAPK and Akt signaling pathways via G protein-coupled receptor in PC-3 prostate cancer cells. Clin. Chim. Acta; Int. J. Clin. Chem. 2007, 383, 78–84. [CrossRef]

40. Koohestani, N.; Chia, M.C.; Pham, N.A.; Tran, T.T.; Minkin, S.; Wolever, T.M.; Bruce, W.R. Aberrant cytokine focus promotion and glucose intolerance: Correlation in the rat across diets differing in fat, n-3 fatty acids and energy. Carcinogenesis 1998, 19, 1679–1684. [CrossRef]

41. Wang, Y.; Corr, J.G.; Thaler, H.T.; Tao, Y.; Fair, W.R.; Heston, W.D. Decreased growth of established human prostate LNCaP tumors against erythrocyte membranes peroxidation: A comparison between healthy subjects and type 1 diabetic patients. J. Proteome Res. 2019, 20, 5379–5391. [CrossRef]

42. Revilla, G.; Cassou, L.; Tondo, M.; Moral, A.; Perez, J.I.; Corcoy, R.; Lerma, E.; Fuste, V.; Reddy, S.T.; Blanco-Vaca, F.; et al. LDL, HDL and endocrine-related cancer: From pathogenic mechanisms to therapies. J. Proteome Res. 2021, 20, 383, e91080. [CrossRef] [PubMed]

43. Arthur, R.; Moller, H.; Garmo, H.; Holmberg, L.; Stattin, P.; Malmstrom, H.; Lambe, M.; Hammar, N.; Walldius, G.; Robinson, D.; et al. Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories. Cancer Med. 2016, 5, 1307–1318. [CrossRef]

44. Asavasupreechar, T.; Chan, M.S.M.; Saito, R.; Miki, Y.; Boonyaratakornkit, V.; Sasano, H. Sex steroid metabolism and actions in human prostate cancer: From pathogenic mechanisms to therapies. J. Proteome Res. 2021, 20, 383, e91080. [CrossRef] [PubMed]

45. Fox, E.M.; Andrade, J.; Shupnik, M.A. Novel actions of estrogen to promote proliferation: Integration of cytoplasmic and nuclear pathways. Steroids 2009, 74, 622–627. [CrossRef]

46. Asavasupreechar, T.; Chan, M.S.M.; Saito, R.; Miki, Y.; Boonyaratakornkit, V.; Sasano, H. Sex steroid metabolism and actions in non-small cell lung carcinoma. J. Steroid Biochem. Mol. Biol. 2019, 193, 105440. [CrossRef] [PubMed]

47. Wang, X.D.; Kim, C.; Zhang, Y.; Rindhe, S.; Cobb, M.H.; Yu, Y. Cholesterol Regulates the Tumor Adaptive Resistance to MAPK Pathway Inhibition. J. Proteome Res. 2021, 20, 5379–5391. [CrossRef]

48. Revilla, G.; Cassou, L.; Tondo, M.; Moral, A.; Perez, J.I.; Corcoy, R.; Lerma, E.; Fuste, V.; Reddy, S.T.; Blanco-Vaca, F.; et al. LDL, HDL and endocrine-related cancer: From pathogenic mechanisms to therapies. Semin. Cancer Biol. 2021, 73, 134–157. [CrossRef] [PubMed]

49. Pirro, M.; Ricciuti, B.; Rader, D.J.; Catapano, A.L.; Sahebkar, A.; Banach, M. High density lipoprotein cholesterol and cancer: Marker or causative? Prog. Lipid Res. 2018, 71, 54–69. [CrossRef]

50. Ferretti, G.; Bacchetti, T.; Busini, D.; Rabini, R.A.; Curatola, G. Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: A comparison between healthy subjects and type 1 diabetic patients. J. Clin. Endocrinol. Metab. 2004, 89, 2957–2962. [CrossRef]

51. Rohatgi, A.; Westerterp, M.; von Eckardstein, A.; Remaley, A.; Rye, K.A. HDL in the 21st Century: A Multifunctional Roadmap for Future HDL Research. Circulation 2021, 143, 2293–2309. [CrossRef]